DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
Adenosineis the generic ingredient in three branded drugs marketed by Astellas, Akorn, Am Regent, Fresenius Kabi Usa, Gland Pharma Ltd, Mylan Labs Ltd, Teva Pharms Usa, West-ward Pharms Int, Wockhardt, Aurobindo Pharma Ltd, Emcure Pharms Ltd, Hospira Inc, and Mylan Asi, and is included in twenty-three NDAs. Additional information is available in the individual branded drug profile pages.
There are twenty-six drug master file entries for adenosine. Fourteen suppliers are listed for this compound. There are two tentative approvals for this compound.
Summary for adenosine
Recent Clinical Trials for adenosine
Identify potential brand extensions & 505(b)(2) entrants
|Alliance for Clinical Trials in Oncology||Phase 3|
|University of Iowa||Phase 2|
|University of Kentucky||Phase 2|
Generic filers with tentative approvals for ADENOSINE
The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.
Pharmacology for adenosine
|Drug Class||Adenosine Receptor Agonist |
|Mechanism of Action||Adenosine Receptor Agonists |
Medical Subject Heading (MeSH) Categories for adenosine
|Applicant||Tradename||Generic Name||Dosage||NDA||Approval Date||TE||Type||RLD||RS||Patent No.||Patent Expiration||Product||Substance||Delist Req.||Exclusivity Expiration|
|Aurobindo Pharma Ltd||ADENOSINE||adenosine||SOLUTION;INTRAVENOUS||205331-002||Nov 2, 2017||AP||RX||No||No||Start Trial||Start Trial||Start Trial|
|Aurobindo Pharma Ltd||ADENOSINE||adenosine||SOLUTION;INTRAVENOUS||205331-001||Nov 2, 2017||AP||RX||No||No||Start Trial||Start Trial||Start Trial|
|Akorn||ADENOSINE||adenosine||INJECTABLE;INJECTION||078076-001||Oct 31, 2008||AP||RX||No||Yes||Start Trial||Start Trial||Start Trial|
|>Applicant||>Tradename||>Generic Name||>Dosage||>NDA||>Approval Date||>TE||>Type||>RLD||>RS||>Patent No.||>Patent Expiration||>Product||>Substance||>Delist Req.||>Exclusivity Expiration|
|Applicant||Tradename||Generic Name||Dosage||NDA||Approval Date||Patent No.||Patent Expiration|
|Astellas||ADENOCARD||adenosine||INJECTABLE;INJECTION||019937-002||Oct 30, 1989||Start Trial||Start Trial|
|Astellas||ADENOSCAN||adenosine||SOLUTION;INTRAVENOUS||020059-002||May 18, 1995||Start Trial||Start Trial|
|Astellas||ADENOSCAN||adenosine||SOLUTION;INTRAVENOUS||020059-001||May 18, 1995||Start Trial||Start Trial|
|>Applicant||>Tradename||>Generic Name||>Dosage||>NDA||>Approval Date||>Patent No.||>Patent Expiration|
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.